Clinical Trials Logo
  1. Home
  2. Shingles
  3. NCT00109122

Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)

Shingles Clinical Trial

Official title:
A Double-Blind, Placebo-Controled, Randomized Study to Evaluate Safety, Tolerability, and Immunogenicity After 1 and 2 Doses of Zoster Vaccine

Clinical Trial Summary

The purpose of this study is to determine the immunity (the body's protection) against shingles after receiving two doses of an investigational vaccine or placebo (a look alike vaccine with no active ingredients).

Clinical Trial Description

The duration of treatment is 12 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00109122
Study type Interventional
Source Merck Sharp & Dohme Corp.
Contact
Status Completed
Phase Phase 2
Start date November 2001
Completion date July 2006
View Details
See also
  Status Clinical Trial Phase
Completed NCT01132716 - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions N/A
Completed NCT01132729 - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions N/A
Completed NCT04099706 - Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT N/A
Completed NCT04540081 - Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer N/A
Completed NCT01527370 - Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025) Phase 3
Completed NCT00534248 - Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022) Phase 3
Completed NCT01262300 - Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents Phase 1
Completed NCT00576108 - A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN) Phase 2
Completed NCT04047979 - Systems Biology of Zoster Vaccine Phase 2
Active, not recruiting NCT05871541 - A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine Phase 1
Completed NCT02114333 - Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds Phase 1
Completed NCT00900783 - A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster Phase 2
Completed NCT01600079 - ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)
Active, not recruiting NCT02444936 - ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors Phase 4
Recruiting NCT05554068 - Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Phase 2
Recruiting NCT06238726 - Nudging Patients to Increase Shingles Vaccination N/A
Completed NCT02704572 - Optimal Timing of Zoster Vaccine After Zoster Illness N/A
Completed NCT00300222 - Study of NGX-4010 for the Treatment of Postherpetic Neuralgia Phase 3
Terminated NCT02412917 - A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia Phase 3
Completed NCT00115310 - Study of NGX-4010 for the Treatment of Postherpetic Neuralgia Phase 3